Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/09/22
Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022PRNewsWire • 02/09/22
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic MastocytosisPRNewsWire • 01/28/22
Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy LeadershipPRNewsWire • 01/10/22
Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic MastocytosisPRNewsWire • 12/06/21
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo TherapeuticsPRNewsWire • 11/29/21
Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater ChinaPRNewsWire • 11/09/21
Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/28/21
Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 10/28/21
Blueprint Medicines to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021PRNewsWire • 10/21/21
Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare ConferencePRNewsWire • 09/02/21
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/29/21
MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 DevelopmentPRNewsWire • 07/28/21